Envoy Medical reports FY2025 revenue $241k; extinguishes $32M debt; completes Acclaim trial enrollment

Envoy Medical, Inc.

FY2025 net revenue $241k, up from $225k (YoY +$16k). No EPS given.
Extinguished over $32M of debt in 2025; cash $3.7M at year-end.
FDA approved expansion of Acclaim cochlear implant pivotal trial to final stage.
Post year-end: closed up to $78M public offering ($30M received); enrolled 56-patient pivotal trial.
IP portfolio grew to 47 patents globally.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Envoy Medical, Inc. reported full year ended December 31, 2025 results: revenue $241.

Period: full year ended December 31, 2025
Revenue: $241
Result: reported results

Exact text from the filing

Net Revenue was $241 as of December 31, 2025 compared to $225 for year ended December 31, 2024.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

Envoy Medical, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-035483

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.